SCHEMBL16390707

SCHEMBL16390707

Cc1cnc(OC(=O)Nc2cccc(C3(C)COCC(N)=N3)c2)cn1

nearest known ligand 0.73

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 20/20 0.73
APP P05067 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16390788 0.93 BACE1 (0.80) BACE1APP
SCHEMBL16390720 0.92 BACE1 (0.68) BACE1APP
SCHEMBL16390855 0.90 BACE1 (0.74) BACE1APP
SCHEMBL16390715 0.87 BACE1 (0.74) BACE1APP
SCHEMBL16390698 0.87 BACE1 (0.74) BACE1APP
SCHEMBL16390629 0.87 BACE1 (0.75) BACE1APP
SCHEMBL16390765 0.87 BACE1 (0.74) BACE1APP
SCHEMBL16390694 0.86 BACE1 (0.76) BACE1APP
SCHEMBL16390634 0.86 BACE1 (0.74) BACE1APP
SCHEMBL16390849 0.86 BACE1 (0.74) BACE1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2456763-B1 OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS NOVARTIS AG (CH) 2015-01-21 EP claimed